Professor Stuart Nicklin

Professor of Cardiovascular Molecular Therapy (Cardiovascular & Metabolic Health)
Dean of Postgraduate Research (MVLS College) (MVLS College Senior Management)

telephone: 01413302521
email: Stuart.Nicklin@glasgow.ac.uk

C429 Level C4, BHF GCRC, School of Cardiovascular & Metabolic Health, 126 University Place, Glasgow, G12 8TA

Biography

Professor of Cardiovascular Molecular Therapy in the School of Cardiovascular and Metabolic Health. After completing his PhD at the Bristol Heart Institute, University of Bristol working on targeting adenoviral gene transfer vectors for cardiovascular gene therapy he then moved to post-doctoral training in the Department of Medicine and Therapeutics at the University of Glasgow. From there he was successful in securing a British Heart Foundation Intermediate Fellowship before an academic position at the University of Glasgow. He has been Principal Investigator on a number of project grants funded by the British Heart Foundation and Medical Research Council and is co-investigator in the BHF Centre of Research Excellence. He is currently Executive Deputy Editor of Cardiovascular Research and on the Editorial Board of Human Gene Therapy, Molecular Therapy, Hypertension and Frontiers in Cardiovascular Medicine- Cardiovascular Biologics and Regenerative Medicine. He is elected to the Executive Board of the British Society for Gene and Cell Therapy as General Secretary.

Research interests

Research Theme: Cardiac Diseases

My primary research interests are in novel therapeutic approaches in cardiovascular disease and in particular the development of cardiovascular gene therapies. We are studying models of myocardial infarction, hypertensive cardiac remodelling and acute vascular injury using gene therapy approaches via viral vector-mediated gene transfer. We also have a key interest in the counter-regulatory renin angiotensin system, both for studies into its molecular mechanisms of action and in identifying and developing novel therapeutic approaches which can be studied using gene transfer and other therapeutic approaches. Ultimately, we aim to identify therapeutic applications which can be developed in cardiovascular disease.

Research:

Counter-regulatory renin angiotensin system
Gene therapy
Viral vectors

Research groups

Publications

List by: Type | Date

Jump to: 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1997 | 1996

Number of items: 113.

2025

Elbassioni, A. A. M. et al. (2025) Targeting Runx1 protects against heart failure with preserved ejection fraction. bioRxiv, (doi: 10.1101/2025.01.24.634831)

McIntosh, B., Elbassioni, A., Raheem, A., MacDonald, E. A. , Nicklin, S. A. , Koay, Y. C., Cameron, E. R. , Loughrey, C. M. and O'Sullivan, J. F. (2025) Optimized protocols for commonly-used murine models of heart failure with preserved ejection fraction. bioRxiv, (doi: 10.1101/2025.01.22.634221)

2024

McFall, A. , Graham, D. , Nicklin, S. A. and Work, L. M. (2024) Unscheduled changes in pre-clinical stroke model housing contributes to variance in physiological and behavioural data outcomes: a post hoc analysis. Brain and Neuroscience Advances, 8, (doi: 10.1177/23982128241238934) (PMID:38516557) (PMCID:PMC10956152)

2023

Martin, T. P. et al. (2023) Ribonucleicacid interference or small molecule inhibition of Runx1 in the border zone prevents cardiac contractile dysfunction following myocardial infarction. Cardiovascular Research, 119(16), 2663–2671-2663–2671. (doi: 10.1093/cvr/cvad107) (PMID:37433039) (PMCID:PMC10730241)

2022

Schwartze, J. T., Havenga, M., Bakker, W. A. M., Bradshaw, A. C. and Nicklin, S. A. (2022) Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. Journal of Molecular Medicine, 100(6), pp. 875-901. (doi: 10.1007/s00109-022-02208-0) (PMID:35606652) (PMCID:PMC9126699)

He, W. et al. (2022) Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 118(6), pp. 1535-1547. (doi: 10.1093/cvr/cvab204) (PMID:34132807)

Divorty, N., Jenkins, L. , Ganguly, A. , Butcher, A. J., Hudson, B. D. , Schulz, S., Tobin, A. B. , Nicklin, S. A. and Milligan, G. (2022) Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. Journal of Biological Chemistry, 298(3), 101655. (doi: 10.1016/j.jbc.2022.101655) (PMID:35101446) (PMCID:PMC8892012)

Martin, T. P. , MacDonald, E. A. , Elbassioni, A. A., Zaeri, A. A. I., O'Toole, D., Nicklin, S. A. , Gray, G. A. and Loughrey, C. M. (2022) Pre-clinical models of myocardial infarction: from mechanism to translation. British Journal of Pharmacology, 179(5), pp. 770-791. (doi: 10.1111/bph.15595) (PMID:34131903)

2021

Bates, E. A. et al. (2021) In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses, 13(8), 1483. (doi: 10.3390/v13081483)

2020

McFall, A. , Nicklin, S. A. and Work, L. M. (2020) The counter regulatory axis of the renin angiotensin system in the brain and ischaemic stroke: insight from preclinical stroke studies and therapeutic potential. Cellular Signalling, 76, 109809. (doi: 10.1016/j.cellsig.2020.109809) (PMID:33059037) (PMCID:PMC7550360)

O'Toole, D., Zaeri, A. A. I., Nicklin, S. A. , French, A. T., Loughrey, C. M. and Martin, T. P. (2020) Signalling pathways linking cysteine cathepsins to adverse cardiac remodelling. Cellular Signalling, 76, 109770. (doi: 10.1016/j.cellsig.2020.109770) (PMID:32891693)

Pashova, A., Work, L.M. and Nicklin, S.A. (2020) The role of extracellular vesicles in neointima formation post vascular injury. Cellular Signalling, 76, 109783. (doi: 10.1016/j.cellsig.2020.109783) (PMID:32956789)

Charla, E., Mercer, J. , Maffia, P. and Nicklin, S. (2020) Extracellular vesicle signalling in atherosclerosis. Cellular Signalling, 75, 109751. (doi: 10.1016/j.cellsig.2020.109751) (PMID:32860954) (PMCID:PMC7534042)

Guzik, T. J. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 116(10), pp. 1666-1687. (doi: 10.1093/cvr/cvaa106) (PMID:32352535) (PMCID:PMC7197627)

Riddell, A. , McBride, M. , Braun, T., Nicklin, S. A. , Cameron, E. , Loughrey, C. M. and Martin, T. P. (2020) RUNX1: an emerging therapeutic target for cardiovascular disease. Cardiovascular Research, 116(8), pp. 1410-1423. (doi: 10.1093/cvr/cvaa034) (PMID:32154891) (PMCID:PMC7314639)

McArthur, L. , Riddell, A. , Chilton, L., Smith, G. L. and Nicklin, S. A. (2020) Regulation of connexin 43 by interleukin 1β in adult rat cardiac fibroblasts and effects in an adult rat cardiac myocyte: fibroblast co-culture model. Heliyon, 6(1), e03031. (doi: 10.1016/j.heliyon.2019.e03031) (PMID:31909243) (PMCID:PMC6940628)

2019

Doszpoly, A., de la Cuesta, F., Lopez-Gordo, E., Bénézech, C., Nicklin, S. A. and Baker, A. H. (2019) Human adenovirus serotype 5 is sensitive to IgM-independent neutralization in vitro and in vivo. Viruses, 11(7), 616. (doi: 10.3390/v11070616) (PMID:31284434) (PMCID:PMC6669743)

Schanstra, J. P. et al. (2019) Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment. JCI Insight, 4(10), e125638. (doi: 10.1172/jci.insight.125638)

Arroja, M.M.C., Reid, E. , Roy, L.A., Vallatos, A.V. , Holmes, W.M. , Nicklin, S.A. , Work, L.M. and McCabe, C. (2019) Assessing the effects of Ang-(1-7) therapy following transient middle cerebral artery occlusion. Scientific Reports, 9, 3154. (doi: 10.1038/s41598-019-39102-8) (PMID:30816157) (PMCID:PMC6395816)

Nather, K., Loughrey, C. M. and Nicklin, S. A. (2019) Vasoactive peptides: renin-angiotensin-aldosterone system. In: Touyz, Rhian M. and Delles, Christian (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 93-101. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_9)

2018

Guzik, T. J. et al. (2018) What matters in Cardiovascular Research? Scientific discovery driving clinical delivery. Cardiovascular Research, 114(12), pp. 1565-1568. (doi: 10.1093/cvr/cvy214)

Divorty, N., Milligan, G. , Graham, D. and Nicklin, S. A. (2018) The orphan receptor GPR35 contributes to angiotensin II–induced hypertension and cardiac dysfunction in mice. American Journal of Hypertension, 31(9), pp. 1049-1058. (doi: 10.1093/ajh/hpy073) (PMID:29860395) (PMCID:PMC6077831)

McCarroll, C. S. et al. (2018) Runx1 deficiency protects against adverse cardiac remodeling after myocardial infarction. Circulation, 137(1), pp. 57-70. (doi: 10.1161/CIRCULATIONAHA.117.028911) (PMID:29030345) (PMCID:PMC5757664)

Delles, C. , Carrick, E., Graham, D. and Nicklin, S. A. (2018) Utilising proteomics to understand and define hypertension: where are we and where do we go? Expert Review of Proteomics, 15(7), pp. 581-592. (doi: 10.1080/14789450.2018.1493927) (PMID:29999442) (PMCID:PMC6092739)

2017

Lopez-Gordo, E., Doszpoly, A., Duffy, M. R., Coughlan, L., Bradshaw, A. C. , White, K. M., Denby, L., Nicklin, S. A. and Baker, A. H. (2017) Defining a novel role for the coxsackie and adenovirus receptor in human adenovirus serotype 5 transduction in vitro in the presence of mouse serum. Journal of Virology, 91(12), e02487-16. (doi: 10.1128/JVI.02487-16) (PMID:28381574) (PMCID:PMC5446653)

2016

Fattah, C. et al. (2016) Gene therapy with Angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction. Journal of the American College of Cardiology, 68(24), pp. 2652-2666. (doi: 10.1016/j.jacc.2016.09.946) (PMID:27978950) (PMCID:PMC5158000)

Nicklin, S. A. (2016) A novel mechanism of action for angiotensin-(1-7) via the angiotensin type 1 receptor. Hypertension, 68(6), pp. 1342-1343. (doi: 10.1161/HYPERTENSIONAHA.116.08215) (PMID:27698064)

Robertson, S., Parker, A. L., Clarke, C., Duffy, M. R., Alba, R., Nicklin, S. A. and Baker, A. H. (2016) Retargeting FX binding-ablated HAdV-5 to vascular cells by inclusion of the RGD-4C peptide in hexon hypervariable region 7 and the HI loop. Journal of General Virology, 97(8), pp. 1911-1916. (doi: 10.1099/jgv.0.000505) (PMID:27189759) (PMCID:PMC5156330)

Duffy, M.R., Doszpoly, A., Turner, G., Nicklin, S.A. and Baker, A.H. (2016) The relevance of coagulation factor X protection of adenoviruses in human sera. Gene Therapy, 23(7), pp. 592-596. (doi: 10.1038/gt.2016.32) (PMID:27014840) (PMCID:PMC4940928)

McCallum, J. E., Mackenzie, A. E., Divorty, N., Clarke, C., Delles, C. , Milligan, G. and Nicklin, S. A. (2016) G protein-coupled receptor 35 mediates human saphenous vein vascular smooth muscle cell migration and endothelial cell proliferation. Journal of Vascular Research, 52(6), pp. 383-395. (doi: 10.1159/000444754) (PMID:27064272) (PMCID:PMC4959467)

2015

Zoccarato, A. et al. (2015) Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2. Circulation Research, 117, pp. 707-719. (doi: 10.1161/CIRCRESAHA.114.305892) (PMID:26243800)

Mckinney, C.A., Kennedy, S. , Baillie, G.S. , Milligan, G. and Nicklin, S.A. (2015) Angiotensin-(1-7) and angiotensin-(1-9) inhibit vascular smooth muscle cell growth and migration in vitro and vascular remodelling in vivo. Atherosclerosis, 241(1), e44. (doi: 10.1016/j.atherosclerosis.2015.04.158)

McArthur, L. , Chilton, L., Smith, G. L. and Nicklin, S. A. (2015) Electrical consequences of cardiac myocyte: fibroblast coupling. Biochemical Society Transactions, 43(3), pp. 513-518. (doi: 10.1042/BST20150035) (PMID:26009200)

Dakin, R. S., Parker, A. L., Delles, C. , Nicklin, S. A. and Baker, A. H. (2015) Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. Human Gene Therapy, 26(5), pp. 312-319. (doi: 10.1089/hum.2015.019) (PMID:25760682) (PMCID:PMC4442572)

Nicklin, S. A. , Griesenbach, U. and Baker, A. H. (2015) Special focus issue on the annual meeting of the british society for gene and cell therapy. Human Gene Therapy, 26(5), pp. 247-248. (doi: 10.1089/hum.2015.2500) (PMID:25989311)

Duffy, M., Ma, J., Deng, L., Dakin, R. S., Uil, T., Custers, J., Kelly, S. M. , McVey, J. H., Nicklin, S. A. and Baker, A. H. (2015) Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo. PLoS Pathogens, 11(2), e1004673. (doi: 10.1371/journal.ppat.1004673) (PMID:25658827) (PMCID:PMC4450073)

Divorty, N., Mackenzie, A., Nicklin, S. and Milligan, G. (2015) G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Frontiers in Pharmacology, 6, 41. (doi: 10.3389/fphar.2015.00041) (PMID:25805994) (PMCID:PMC4354270)

2014

Lopez Gordo, E., Denby, L., Nicklin, S. A. and Baker, A. H. (2014) The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery. Expert Opinion on Drug Delivery, 11(11), pp. 1795-1813. (doi: 10.1517/17425247.2014.938637)

McKinney, C. A., Fattah, C., Loughrey, C. M. , Milligan, G. and Nicklin, S. A. (2014) Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodeling. Clinical Science, 126, pp. 815-827. (doi: 10.1042/CS20130436)

McLachlan, J., Beattie, E., Murphy, M. P., Koh-Tan, C. H.H., Olson, E., Beattie, W., Dominiczak, A. F. , Nicklin, S. A. and Graham, D. (2014) Combined therapeutic benefit of mitochondria-targeted antioxidant, MitoQ10, and angiotensin receptor blocker, losartan, on cardiovascular function. Journal of Hypertension, 32(3), pp. 555-564. (doi: 10.1097/HJH.0000000000000054)

Mackenzie, A.E. et al. (2014) The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat gpr35. Molecular Pharmacology, 85(1), pp. 91-104. (doi: 10.1124/mol.113.089482)

2013

Baker, A.H., Nicklin, S.A. and Shayakhmetov, D.M. (2013) FX and host defense evasion tactics by adenovirus. Molecular Therapy, 21(6), pp. 1109-1111. (doi: 10.1038/mt.2013.100)

Clarke, C., Flores-Muñoz, M., McKinney, C. A., Milligan, G. and Nicklin, S. A. (2013) Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin–angiotensin system. Future Cardiology, 9(1), pp. 23-38. (doi: 10.2217/fca.12.75)

Jenkins, L. , Harries, N., Lappin, J.E., MacKenzie, A.E., Neetoo-Isseljee, Z., Southern, C., McIver, E.G., Nicklin, S.A. , Taylor, D.L. and Milligan, G. (2013) Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. Journal of Pharmacology and Experimental Therapeutics, 343(3), pp. 683-695. (doi: 10.1124/jpet.112.198945) (PMID:22967846) (PMCID:PMC3500541)

Parker, A. L., Bradshaw, A. C. , Alba, R., Nicklin, S. A. and Baker, A. H. (2013) Capsid modification strategies for detargeting adenoviral vectors. In: Chillon, M. and Bosch, A. (eds.) Adenovirus: Methods and Protocols [3rd.]. Series: Methods in molecular biology (1089). Humana Press, pp. 45-59. ISBN 9781627036788 (doi: 10.1007/978-1-62703-679-5_3)

2012

Bradshaw, A. C. , Coughlan, L., Miller, A. M.., Nicklin, S. A. , Baker, A. H., Alba, R. and van Rooijen, N. (2012) Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. Journal of Controlled Release, 164(3), pp. 394-402. (doi: 10.1016/j.jconrel.2012.05.025)

Coughlan, L. et al. (2012) Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Molecular Therapy, 20(12), pp. 2268-2281. (doi: 10.1038/mt.2012.162) (PMID:22929662) (PMCID:PMC3514487)

Robertson, K.E., McDonald, R.A., Oldroyd, K.G., Nicklin, S.A. and Baker, A.H. (2012) Prevention of coronary in-stent restenosis and vein graft failure: Does vascular gene therapy have a role? Pharmacology and Therapeutics, 136(1), pp. 23-34. (doi: 10.1016/j.pharmthera.2012.07.002)

Alba, R., Baker, A. H. and Nicklin, S. (2012) Vector systems for prenatal gene therapy: principles of adenovirus design and production. In: Coutelle, Coutelle and Waddington, Simon N. (eds.) Prenatal Gene Therapy: Concepts, Methods, and Protocols. Series: Methods and protocols (891). Humana Press: Totowa, NJ, pp. 55-84. ISBN 9781617798726 (doi: 10.1007/978-1-61779-873-3_4)

Flores, M., Graham, D. , Dominiczak, A.F. , Milligan, G. , Baker, A.H. and Nicklin, S.A. (2012) Angiotensin-(1-9) antagonises Angiotensin II-induced cardiac remodeling via the angiotensin type 2 receptor. Proceedings of the Physiological Society, 27, C1.

Flores, M., Work, L.M. , Douglas, K., Denby, L., Dominiczak, A.F. , Graham, D. and Nicklin, S.A. (2012) Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension, 59(2), pp. 300-307. (doi: 10.1161/HYPERTENSIONAHA.111.177485)

Flores, M., Graham, D. , Dominiczak, A. F. , Milligan, G. , Baker, A. H. and Nicklin, S. A. (2012) Abstract 231: angiotensin-(1-9) antagonises cardiac remodelling in a mouse model of Angiotensin Ii-induced hypertension. Hypertension, 60, A231.

Flores-Muñoz, M., Godinho, B.M.D.C., Almalik, A. and Nicklin, S.A. (2012) Adenoviral delivery of angiotensin-(1-7) or angiotensin-(1-9) inhibits cardiomyocyte hypertrophy via the mas or angiotensin Type 2 receptor. PLoS ONE, 7(9), e45564. (doi: 10.1371/journal.pone.0045564) (PMID:23029101) (PMCID:PMC3447802)

2011

Mackenzie, A.E., Lappin, J.E., Taylor, D.L., Nicklin, S.A. and Milligan, G. (2011) GPR35 as a novel therapeutic target. Frontiers in Endocrinology, 2, 68. (doi: 10.3389/fendo.2011.00068) (PMID:22654822) (PMCID:PMC3356001)

Flores-Munoz, M., Smith, N. J., Haggerty, C., Milligan, G. and Nicklin, S. A. (2011) Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. Journal of Physiology, 589(4), pp. 939-951. (doi: 10.1113/jphysiol.2010.203075)

2010

Alba, R. et al. (2010) Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood, 14(116), pp. 2656-2664. (doi: 10.1182/blood-2009-12-260026)

Bradshaw, A.C. , Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., Kahari, V.M., Nicklin, S.A. and Baker, A.H. (2010) Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens, 6(10), e1001142. (doi: 10.1371/journal.ppat.1001142)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C. , Mcneish, I.A. , Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi: 10.3390/v2102290) (PMID:21994621) (PMCID:PMC3185574)

Nicklin, S. A. and Baker, A. H. (2010) Adenoviral vectors. In: Herzog, Roland W. and Zolotukhin, Sergei (eds.) A Guide to Human Gene Therapy. World Scientific Publishing, pp. 21-36. ISBN 9789814280907 (doi: 10.1142/9789814280914_0002)

Padmanabhan, S. et al. (2010) Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genetics, 6(10), e1001177. (doi: 10.1371/journal.pgen.1001177)

2009

Masson, R., Nicklin, S. A. and Baker, A. H. (2009) Gene delivery to cardiovascular tissue. In: Abraham, D., Handler, C., Dashwood, M. and Coghlan, G. (eds.) Advances in Vascular Medicine. Springer London, pp. 25-54. ISBN 9781848826366 (doi: 10.1007/978-1-84882-637-3_2)

Alba, R. et al. (2009) Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood, 114(5), pp. 965-971. (doi: 10.1182/blood-2009-03-208835)

Nicol, C. G., Denby, L., Lopez-Franco, O., Masson, R., Halliday, C. A., Nicklin, S. A., Kritz, A., Work, L. M. and Baker, A. H. (2009) Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Letters, 583(12), pp. 2100-2107. (doi: 10.1016/j.febslet.2009.05.037)

Kettlewell, S., Cabrero, P., Nicklin, S.A. , Dow, J.A.T., Davies, S.A. and Smith, G.L. (2009) Changes of intra-mitochondrial Ca2+ in adult ventricular cardiomyocytes examined using a novel fluorescent Ca2+ indicator targeted to mitochondria. Journal of Molecular and Cellular Cardiology, 46(6), pp. 891-901. (doi: 10.1016/j.yjmcc.2009.02.016) (PMID:19249308)

Parker, A.L., Waddington, S.N., Buckley, S.M.K., Custers, J., Havenga, M.J.E., van Rooijen, N., Goudsmit, J., Mcvey, J.H., Nicklin, S.A. and Baker, A.H. (2009) Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. Journal of Virology, 83(1), pp. 479-483. (doi: 10.1128/JVI.01878-08)

Greig, J.A. et al. (2009) Influence of Coagulation Factor X on In Vitro and In Vivo Gene Delivery by Adenovirus (Ad) 5, Ad35, and Chimeric Ad5/Ad35 Vectors. Molecular Therapy, 17(10), pp. 1683-1691. (doi: 10.1038/mt.2009.152)

Lenaerts, L., Mcvey, J., Baker, A., Denby, L., Nicklin, S., Verbeken, E. and Naesens, L. (2009) Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. Journal of Gene Medicine, 11(2), pp. 119-127. (doi: 10.1002/jgm.1283)

Masson, R. et al. (2009) Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2. Hypertension, 53(4), pp. 694-700. (doi: 10.1161/HYPERTENSIONAHA.108.122333)

2008

Parker, A.L., Nicklin, S.A. and Baker, A.H. (2008) Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Current Opinion in Molecular Therapeutics, 10(5), pp. 439-448.

White, K. et al. (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Therapy, 15(6), pp. 443-451. (doi: 10.1038/sj.gt.3303077)

Waddington, S. et al. (2008) Adenovirus serotype 5 hexon mediates liver gene transfer. Cell, 132(3), pp. 397-409. (doi: 10.1016/j.cell.2008.01.016)

Flores-Munoz, M., Baker, A. and Nicklin, S. (2008) Development of a gene transfer vector expressing angiotensin 1-7 and assessment of its effects on cardiac hypertrophy. Journal of Human Hypertension, 22(10), p. 723.

Greig, J., Mcvey, J., Waddington, S., Parker, A., Buckley, S., Havenga, M., Nicklin, S. and Baker, A. (2008) Factor X enhances binding and transduction of human cancer cell lines by adenovirus (Ad) serotype 5 vectors but not by Ad35. Human Gene Therapy, 19(4), p. 398.

Nicklin, S. and Baker, A. (2008) Efficient Vascular Endothelial Gene Transfer Following Intravenous Adenovirus Delivery. Molecular Therapy, 16(12), pp. 1904-1905. (doi: 10.1038/mt.2008.226)

Parker, A., Parker, A., Mcvey, J., Waddington, S., Buckley, S., Francischetti, I., Monteiro, R., Nicklin, S. and Baker, A. (2008) An exosite within the human FX serine protease domain mediates cell transduction of AD5: FX complexes. Human Gene Therapy, 19(4), p. 34.

2007

Waddington, S.N., Parker, A.L., Havenga, M., Nicklin, S.A., Buckley, S.M., McVey, J.H. and Baker, A.H. (2007) Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: Fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. Journal of Virology, 81(17), pp. 9568-9571. (doi: 10.1128/JVI.00663-07)

Kritz, A. B., Nicol, C. G., Dishart, K. L., Nelson, R., Holbeck, S., Von Seggern, D. J., Work, L. M., Mcvey, J. H., Nicklin, S. A. and Baker, A. H. (2007) Adenovirus 5 fibers mutated at the putative HSPG-binding site show restricted retargeting with targeting peptides in the HI loop. Molecular Therapy, 15, pp. 741-749. (doi: 10.1038/sj.mt.6300094)

Denby, L., Work, L.M., Von Seggern, D.J., Wu, E., Mcvey, J.H., Nicklin, S.A. and Baker, A.H. (2007) Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Molecular Therapy, 15(9), pp. 1647-1654. (doi: 10.1038/sj.mt.6300214)

Parker, A., Mcvey, J., Doctor, J., Lopez-Franco, O., Waddington, S., Havenga, M., Nicklin, S. and Baker, A. (2007) Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. Journal of Virology, 81, pp. 3627-3631. (doi: 10.1128/JVI.02786-06)

White, K., Nicklin, S. and Baker, A. (2007) Novel vectors for in vivo gene delivery to vascular tissue. Expert Opinion on Biological Therapy, 7(6), pp. 809-821. (doi: 10.1517/14712598.7.6.809)

2006

Parker, A.L. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes in vitro and in vivo. Blood, 108(8), pp. 2554-2561. (doi: 10.1182/blood-2006-04-008532)

Parker, A. et al. (2006) Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood, 108, pp. 2554-2561. (doi: 10.1182/blood-2006-04-008532)

Work, L.M. et al. (2006) Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Molecular Therapy, 13(4), pp. 683-693. (doi: 10.1016/j.ymthe.2005.11.013)

2005

Baker, A., Kritz, A., Work, L., Nicklin, S. and Nicklin, A. (2005) Cell-selective viral gene delivery vectors for the vasculature. Experimental Physiology, 90(1), pp. 27-31. (doi: 10.1113/expphysiol.2004.028126)

Denby, L., Nicklin, S.A. and Baker, A.H. (2005) Adeno-associated virus (AAV)-7 and-8 poorly transduce vascular endothelial cells and are sensitive to proteasomal degradation. Gene Therapy, 12, pp. 1534-1538. (doi: 10.1038/sj.gt.3302564)

Miller, W.H. , Nicklin, S.A. , Baker, A.H. and Dominiczak, A. (2005) Gene transfer and cardiovascular system. In: Raizada, M.K., Paton, J.F.R., Kasparov, S. and Katovich, M.J. (eds.) Cardiovascular Genomics. Series: Contemporary cardiology. Humana Press: Totowa, NJ, USA, pp. 175-196. ISBN 9781588294005

Nicklin, S., Wu, E., Nemerow, G. and Baker, A. (2005) The influence of adenovirus fiber structure and function on vector development for gene therapy. Molecular Therapy, 12(3), pp. 384-393. (doi: 10.1016/j.ymthe.2005.05.008)

Parker, A., Fisher, K., Oupicky, D., Read, M., Nicklin, S., Baker, A. and Seymour, L. (2005) Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting, 13, pp. 39-51. (doi: 10.1080/10611860400020449)

2004

Denby, L., Work, L.M., Graham, D. , Hsu, C., Von Seggern, D.J., Nicklin, S.A. and Baker, A.H. (2004) Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Human Gene Therapy, 15(11), pp. 1054-1064.

Nicklin, S., White, S., Nicol, C., Von Seggern, D. and Baker, A. (2004) In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. Journal of Gene Medicine, 6, pp. 300-308. (doi: 10.1002/jgm.526)

Nicol, C., Graham, D., Miller, W., White, S., Smith, T., Nicklin, S., Stevenson, S. and Baker, A. (2004) Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Molecular Therapy, 10(2), pp. 344-354. (doi: 10.1016/j.ymthe.2004.05.020)

Papadakis, E., Nicklin, S., Baker, A. and White, S. (2004) Promoters and control elements: Designing expression cassettes for gene therapy. Current Gene Therapy, 4, pp. 89-113.

Wan, S., George, S., Nicklin, S., Yim, A. and Baker, A. (2004) Overexpression of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Molecular Therapy, 9(5), pp. 689-698. (doi: 10.1016/j.ymthe.2004.02.005)

White, S., Nicklin, S., Buning, H., Brosnan, M., Leike, K., Papadakis, E., Hallek, M. and Baker, A. (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation, 109, pp. 513-519. (doi: 10.1161/01.CIR.0000109697.68832.5D)

Work, L., Nicklin, S., Brain, N., Dishart, K., Von Seggern, D., Hallek, M., Buning, H. and Baker, A. (2004) Development of efficient viral vectors selective for vascular smooth muscle cells. Molecular Therapy, 9(2), pp. 198-208. (doi: 10.1016/j.ymthe.2003.11.006)

Work, L., Ritchie, N., Nicklin, S., Reynolds, P. and Baker, A. (2004) Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Therapy, 11, pp. 1296-1300. (doi: 10.1038/sj.gt.3302292)

2003

Buning, H., Nicklin, S., Perabo, L., Hallek, M. and Baker, A. (2003) AAV-based gene transfer. Current Opinion in Molecular Therapeutics, 5, pp. 367-375.

Dishart, K.L. et al. (2003) Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapy. Journal of Molecular and Cellular Cardiology, 35(7), pp. 739-748. (doi: 10.1016/S0022-2828(03)00136-6)

Nicklin, S.A. and Baker, A.H. (2003) Development of targeted viral vectors for cardiovascular gene therapy. In: Setlow, J.K. (ed.) Genetic Engineering, Principles and Methods. Kluwer Academic: Dordrecht, The Netherlands, pp. 15-49. ISBN 9780306477768

Nicklin, S., Dishart, K., Buening, H., Reynolds, P., Hallek, M., Nemerow, G., Von Seggern, D. and Baker, A. (2003) Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Letters, 201, pp. 165-173. (doi: 10.1016/j.canlet.2003.07.003)

Work, L., Nicklin, S. and Baker, A. (2003) Targeting Gene Therapy Vectors to the Vascular Endothelium. Current Atherosclerosis Reports, 5(3), pp. 163-170.

2002

Fennell, J., Brosnan, M., Frater, A., Hamilton, C., Alexander, M., Nicklin, S., Heistad, D., Baker, A. and Dominiczak, A. (2002) Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Therapy, 9(2), pp. 110-117. (doi: 10.1038/sj.gt.3301633)

Nicklin, S. and Baker, A. (2002) Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy. Current Gene Therapy, 2(3), pp. 273-293.

Work, L. M. , Nicklin, S. A. , White, S. J. and Baker, A. H. (2002) Use of phage display to identify novel peptides for targeted gene therapy. In: Phillips, M. Ian (ed.) Gene Therapy Methods. Series: Methods in enzymology (346). Academic Press: San Diego, California ; London, pp. 157-176. ISBN 9780121822477 (doi: 10.1016/S0076-6879(02)46055-7)

2001

Nicklin, S., Buening, H., Dishart, K., De Alwis, M., Girod, A., Hacker, U., Thrasher, A., Ali, R., Hallek, M. and Baker, A. (2001) Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Molecular Therapy, 4(2), pp. 174-181. (doi: 10.1006/mthe.2001.0424)

Nicklin, S., Reynolds, P., Brosnan, M., White, S., Curiel, D., Dominiczak, A. and Baker, A. (2001) Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension, 38(1), pp. 65-70. (doi: 10.1161/01.HYP.38.1.65)

Nicklin, S., Von Seggern, D., Work, L., Pek, D., Dominiczak, A., Nemerow, G. and Baker, A. (2001) Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Molecular Therapy, 4(6), pp. 534-542. (doi: 10.1006/mthe.2001.0489)

Reynolds, P., Nicklin, S., Kaliberova, L., Boatman, B., Grizzle, W., Balyasnikova, I., Baker, A., Danilov, S. and Curiel, D. (2001) Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nature Biotechnology, 19, pp. 838-842.

White, S., Nicklin, S., Sawamura, T. and Baker, A. (2001) Identification of peptides that target the endothelial cell-specific LOX-1 receptor. Hypertension, 37, pp. 449-455.

2000

Nicklin, S. A. , White, S. J., Watkins, S. J., Hawkins, R. E. and Baker, A. H. (2000) Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation, 102(2), pp. 231-237. (doi: 10.1161/01.CIR.102.2.231) (PMID:10889136)

1999

Nicklin, S. A. and Baker, A. H. (1999) Simple methods for preparing recombinant adenoviruses for high-efficiency transduction of vascular cells. In: Baker, Andrew H. (ed.) Vascular Disease: Molecular Biology and Gene Transfer Protocols. Series: Methods in molecular medicine (30). Humana Press: Totowa, NJ, pp. 271-284. ISBN 9780896037311 (doi: 10.1385/1-59259-247-3:271)

1997

Roberts, A. G., Whatley, S. D., Nicklin, S. , Worwood, M., Pointon, J. J., Stone, C. and Elder, G. H. (1997) The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology, 25(1), pp. 159-161. (doi: 10.1002/hep.510250129) (PMID:8985283)

1996

Worwood, M., Dorak, M.T., Nicklin, S. , Stone, C., Pointon, J. and Darke, C. (1996) The frequency of the haemochromatosis-associated genotype D6S265-1:D6S105-8 in blood donors. British Journal of Haematology, 93(4), pp. 838-840. (doi: 10.1046/j.1365-2141.1996.d01-1732.x) (PMID:8703814)

This list was generated on Fri Apr 18 14:26:11 2025 BST.

Jump to: Articles | Book Sections